About the Company
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGEN News
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 14, 2024 Agenus Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations ...
Analysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts Dramatically
The latest analyst coverage could presage a bad day for Agenus Inc. (NASDAQ:AGEN), with the analysts making across-the-board ...
Buy Rating Affirmed for Agenus Amidst Promising Cancer Immunotherapy Developments and Strategic Financial Moves
Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Agenus (AGEN – Research Report). The associated price ...
Agenus Poised for Growth: Anticipated BLA Filing and Promising Clinical Data Underpin Buy Rating
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agenus (AGEN – Research Report), with a price ...
Earnings call: Agenus Inc. outlines robust cancer program and financials
Agenus Inc . (NASDAQ:AGEN), a biotechnology company specializing in immuno-oncology, shared its Fourth Quarter and Full-Year 2023 results, emphasizing their promising BOT/BAL program for cancer ...
Agenus: Q4 Earnings Snapshot
LEXINGTON, Mass. — LEXINGTON, Mass. — Agenus Inc. (AGEN) on Thursday reported a loss of $48.6 million in its fourth quarter. The Lexington, Massachusetts-based company said it had a loss of 13 ...
Agenus: Q4 Earnings Snapshot
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Agenus Inc. (AGEN) on Thursday reported a loss of $48.6 million in its fourth quarter. The Lexington, Massachusetts-based company said it had a loss of ...
Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript
My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Agenus Inc. Fourth Quarter and Full-Year 2023 Results Conference Call.
Loading the latest forecasts...